



NEONATAL

CEFTRIAZONE




This document should be read in conjunction with this [DISCLAIMER](#)

Restricted: Require Microbiologist review within 24 hours of initiation

Presentation	Vial: 1g (powder for reconstitution)
Classification	Third generation cephalosporin
Indication	Used to treat infections caused by susceptible organisms
Contraindication	Use with caution in patients with hypersensitivity or mild adverse reactions to penicillins or carbapenems as cross-reactivity can occur (e.g. rash)
Dose	IV/IM: Sepsis: 50mg/kg/dose once a day Meningitis: Loading dose : 100mg/kg, followed by; Maintenance dose 80mg/kg/dose once daily
Monitoring	Full blood count, urea and electrolytes, Liver function tests
Compatible Fluids	Glucose 5% Glucose 10% Sodium chloride 0.9%

Preparation	<p><u>IV:</u> Available from CIVAS (KEMH & PCH)</p> <p>Step 1: Reconstitute 1g vial with 9.6mL of Water for Injections Concentration is 1g/10mL = 1000mg/10mL</p> <p>Step 2 : Take 2mL of the above solution (200mg) and make up to a final volume of 5mL Concentration is 200mg/5mL <u>Final Concentration = 40mg/mL</u></p> <p><u>IM:</u> Add 3.5 mL lidocaine (lignocaine) 1% to 1 g vial Concentration is 1g/4mL <u>Final concentration is 250mg/mL</u></p>
Administration	<p><u>IV:</u> Give slowly over 3 to 5 minutes</p> <p><u>IV Infusion:</u> Infuse over 30 minutes via syringe pump</p> <p><u>IM:</u> As per NCCU policy. Avoid if possible due to increased incidence of pain</p>
Adverse Reactions	<p>Common: Diarrhoea, candidiasis</p> <p>Infrequent: Skin rashes, transient gallbladder precipitation associated with abdominal pain, nausea vomiting</p> <p>Rare: Neutropenia, eosinophilia, increase in bleeding time</p>
Storage	Vial: Store at room temperature -below 25 °C. Protect from light.
Interactions	Calcium and ceftriaxone are incompatible and a precipitate may form. Ceftriaxone must not be given simultaneously with calcium-containing solutions. Flush lines well in between administrations
Notes	Each 1g of ceftriaxone contains 3.6mmol (83mg) of sodium

References	<p>Ainsworth SB. Neonatal formulary 7: drug use in pregnancy and the first year of life. Seventh ed. Chichester (West Sussex): John Wiley & Sons Inc.; 2015. p140</p> <p>Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2401. 2, p391-393.</p> <p>Truven Health Analytics. Ceftriaxone. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Oct 4]. Available from: https://neofax.micromedexsolutions.com/</p> <p>Society of Hospital Pharmacists of Australia. Ceftriaxone. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Aug 12]. Available from: http://aidh.hcn.com.au</p> <p>Ceftriaxone. In British national formulary for children Joint Formulary Committee (September 2018-19) <i>BNF 74: September 2018-19</i>. London: Pharmaceutical Press</p>
-------------------	--

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	January 2001	Version:	3.0
Last reviewed:	October 2019	Next review date:	Oct 2022
Endorsed by:	Neonatal Directorate Management Group	Date:	Oct 2019
Standards Applicable:	NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety;		

**Printed or personally saved electronic copies of this document are considered uncontrolled.
Access the current version from the WNHS website.**

© Department of Health Western Australia 2019